Chardan Capital Decreases Earnings Estimates for Femasys

Femasys Inc. (NASDAQ:FEMY) – Chardan Capital decreased their FY2024 earnings estimates for shares of Femasys in a report issued on Wednesday, November 13th. Chardan Capital analyst K. Nakae now expects that the company will post earnings per share of ($0.84) for the year, down from their previous estimate of ($0.79). Chardan Capital has a “Buy” rating and a $8.00 price objective on the stock. The consensus estimate for Femasys’ current full-year earnings is ($0.84) per share. Chardan Capital also issued estimates for Femasys’ FY2025 earnings at ($0.49) EPS.

Separately, HC Wainwright reiterated a “buy” rating and issued a $12.00 price target on shares of Femasys in a research report on Tuesday, November 12th.

Femasys Trading Down 2.8 %

Shares of Femasys stock opened at $0.95 on Monday. The business has a fifty day simple moving average of $1.16 and a 200-day simple moving average of $1.14. Femasys has a fifty-two week low of $0.73 and a fifty-two week high of $2.40. The firm has a market cap of $21.82 million, a price-to-earnings ratio of -1.18 and a beta of -2.83. The company has a quick ratio of 5.93, a current ratio of 3.94 and a debt-to-equity ratio of 0.86.

Femasys (NASDAQ:FEMY) last announced its earnings results on Tuesday, November 12th. The company reported ($0.24) EPS for the quarter, missing the consensus estimate of ($0.20) by ($0.04). The firm had revenue of $0.55 million for the quarter, compared to the consensus estimate of $0.40 million. Femasys had a negative return on equity of 141.49% and a negative net margin of 1,435.77%.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of FEMY. Aljian Capital Management LLC bought a new stake in shares of Femasys during the 3rd quarter worth $27,000. XTX Topco Ltd increased its stake in Femasys by 123.9% in the 3rd quarter. XTX Topco Ltd now owns 32,535 shares of the company’s stock worth $36,000 after purchasing an additional 18,004 shares in the last quarter. Geode Capital Management LLC lifted its stake in Femasys by 9.2% during the third quarter. Geode Capital Management LLC now owns 206,483 shares of the company’s stock valued at $229,000 after buying an additional 17,473 shares in the last quarter. Finally, CM Management LLC boosted its holdings in shares of Femasys by 6.3% in the second quarter. CM Management LLC now owns 425,000 shares of the company’s stock worth $484,000 after buying an additional 25,000 shares during the period. Institutional investors own 65.27% of the company’s stock.

Femasys Company Profile

Femasys Inc, a biomedical company, develops therapeutic and diagnostic solutions to address unmet women healthcare needs worldwide. The company provides FemVue saline-air device, a contrast-generating product in the United States, Canada, Japan, and Hong Kong; FemCath, a cornual balloon catheter, a single intrauterine directional delivery product that allows for selective evaluation of an individual fallopian tube; and FemCerv, a biopsy device for endocervical curettage, which can be used to sample cervical cells and tissue circumferentially with sample containment within the device to minimize contamination.